KR20240146018A - Pde5 억제제, 아르기닌 및 n-아세틸시스테인을 포함하는 혈관 질병 치료를 위한 화합물의 병용 - Google Patents

Pde5 억제제, 아르기닌 및 n-아세틸시스테인을 포함하는 혈관 질병 치료를 위한 화합물의 병용 Download PDF

Info

Publication number
KR20240146018A
KR20240146018A KR1020247028842A KR20247028842A KR20240146018A KR 20240146018 A KR20240146018 A KR 20240146018A KR 1020247028842 A KR1020247028842 A KR 1020247028842A KR 20247028842 A KR20247028842 A KR 20247028842A KR 20240146018 A KR20240146018 A KR 20240146018A
Authority
KR
South Korea
Prior art keywords
combination
arginine
pharmaceutical combination
sildenafil
acetylcysteine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247028842A
Other languages
English (en)
Korean (ko)
Inventor
밍 웨이 차오
친 훙 린
포 퉁 첸
Original Assignee
퓨처 팜테크 아이엔씨.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 퓨처 팜테크 아이엔씨. filed Critical 퓨처 팜테크 아이엔씨.
Publication of KR20240146018A publication Critical patent/KR20240146018A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020247028842A 2022-02-09 2023-02-09 Pde5 억제제, 아르기닌 및 n-아세틸시스테인을 포함하는 혈관 질병 치료를 위한 화합물의 병용 Pending KR20240146018A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
TW111104639A TWI859506B (zh) 2022-02-09 2022-02-09 化合物組合用於製作血管疾病治療藥的用途
TW111104639 2022-02-09
PCT/GB2023/050296 WO2023152500A1 (en) 2022-02-09 2023-02-09 Combination of compounds for treating vascular diseases comprising pde5 inhibitor, arginine and n-acetylcysteine

Publications (1)

Publication Number Publication Date
KR20240146018A true KR20240146018A (ko) 2024-10-07

Family

ID=85283927

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247028842A Pending KR20240146018A (ko) 2022-02-09 2023-02-09 Pde5 억제제, 아르기닌 및 n-아세틸시스테인을 포함하는 혈관 질병 치료를 위한 화합물의 병용

Country Status (8)

Country Link
US (1) US20250134892A1 (https=)
EP (1) EP4475833A1 (https=)
JP (1) JP2025504219A (https=)
KR (1) KR20240146018A (https=)
CN (1) CN116808224A (https=)
AU (1) AU2023219232A1 (https=)
TW (1) TWI859506B (https=)
WO (1) WO2023152500A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025046207A1 (en) * 2023-08-31 2025-03-06 Future Pharmtech Inc. New use of a pde 5 inhibitor combination in promoting neurite outgrowth
TWI879058B (zh) * 2023-08-31 2025-04-01 未來新藥股份有限公司 Pde5抑制劑組合於促進神經突生長之新穎用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4699299A (en) 1998-06-26 2000-01-17 Nutracorp Scientific, Inc. Promoting nitric oxide and cyclic gmp activity
IL132460A0 (en) * 1999-10-19 2001-03-19 Laniado Shlomo Sildenafil preparation

Also Published As

Publication number Publication date
CN116808224A (zh) 2023-09-29
JP2025504219A (ja) 2025-02-06
US20250134892A1 (en) 2025-05-01
TW202332450A (zh) 2023-08-16
AU2023219232A1 (en) 2024-07-25
WO2023152500A1 (en) 2023-08-17
EP4475833A1 (en) 2024-12-18
TWI859506B (zh) 2024-10-21

Similar Documents

Publication Publication Date Title
US10137099B2 (en) Activation of AMP-protein activated kinase by oxaloacetate compounds
KR20240146018A (ko) Pde5 억제제, 아르기닌 및 n-아세틸시스테인을 포함하는 혈관 질병 치료를 위한 화합물의 병용
WO2002003996A1 (en) Use of dammarane-type tritepenoid saporins
Yue et al. Tanshinones inhibit NLRP3 inflammasome activation by alleviating mitochondrial damage to protect against septic and gouty inflammation
JP4411414B2 (ja) 糖尿病性神経障害の治療に対する組成物及びその方法
JPH09278663A (ja) カイガンショウからの抽出物（ＰｙｃｎｏｇｅｎｏｌＴＭ） の経口投与によるヒト血小板の反応性の調節方法
Fuentes et al. Protection against indomethacin-induced loss of intestinal epithelial barrier function by a quercetin oxidation metabolite present in onion peel: In vitro and in vivo studies
KR101516677B1 (ko) 지방성 간 질환의 치료용 의약 조성물
de Queiroz et al. Semicarbazone derivatives as promising therapeutic alternatives in leishmaniasis
EP0003827A1 (en) Antidepressant combination
Gour et al. Epicatechin exerts dual action to shield sickling and hydroxyurea-induced myelosuppression: Implication in sickle cell anemia management
JP5808772B2 (ja) 肝細胞内のミトコンドリアの活性化方法
KR20240040767A (ko) His 저감반응자의 치료
AU2006321942A1 (en) Methods and compositions for the treatment of disease
Boitel et al. Antiparasitic treatments in pregnant women: Update and recommendations
Dalal et al. A systematic overview of bexagliflozin: A type 2 diabetic drug
Chen et al. Drug-drug interaction between paxlovid and tacrolimus in a patient with myasthenia gravis and SARS-CoV-2 infection
WO2025026900A1 (en) Compounds for the treatment or prevention of gout
US20130338203A1 (en) TREATMENT OF ARTERIAL AGEING BY COMBINATION OF RAAS INHIBITOR AND HMG-CoA REDUCTASE INHIBITOR
CA3218585A1 (en) Composition for treating autoimmune, alloimmune, inflammatory, and mitochondrial conditions, and uses thereof
Bartko et al. Recombinant human diamine oxidase activity is not inhibited by ethanol, acetaldehyde, disulfiram, diethyldithiocarbamate or cyanamide
JP7837595B2 (ja) 動脈硬化を含む老化関連血管疾患の治療又は予防用組成物としてのサイコサポニンｃ
KR20140147799A (ko) 독성유발기 및 n-아세틸-l-시스테인 중 적어도 어느 하나를 포함하는 의약품을 포함하는 약학조성물
US20240066017A1 (en) Prevention or treatment of brain disease and adverse effects of cholinesterase inhibitors
EP4591861A1 (en) Use of 4-tmap for treating or relieving depression

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R15-X000 Change to inventor requested

St.27 status event code: A-3-3-R10-R15-oth-X000

R16-X000 Change to inventor recorded

St.27 status event code: A-3-3-R10-R16-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000